Newly Identified TPI Deficiency Treatments Function for Novel Disease-Causing Allele, TPI1R5G
Authors:
- Joseph R. FiguraJFJoseph R. Figura
- Presley RobertsPRPresley Roberts
- Riley SawkaRSRiley Sawka
- Maci ChambersMCMaci Chambers
- Marcelo ClaudioMCMarcelo Claudio
- Laura L. VollmerLVLaura L. Vollmer
- Andreas VogtAVAndreas Vogt
- Gregg E. HomanicsGHGregg E. Homanics
- Eduard van BeersEBEduard van Beers
- Mylene DongeMDMylene Donge
- Emmanuel ScalaisESEmmanuel Scalais
- Arthur SorlinASArthur Sorlin
Open Access
Abstract
Background/Objectives: Triosephosphate Isomerase (TPI) is a glycolytic enzyme known to be associated with TPI deficiency, a severe form of childhood-onset glycolytic enzymopathy associated with hemolytic anemia, neuromuscular impairment and early death. Most often the disease results from the common TPI1E105D mutation, which can be either homozygous or compound heterozygous with another allele. Methods: We purified TPIR5G protein, studied mutant protein biochemistry, established and characterized TPIR5G/f.s.patient cells, and investigated newly identified compounds for their efficacy in vitro using Western blot and TPI activity assays. Results: We identified novel TPI1 alleles that result in TPI Deficiency with an atypical presentation lacking anemia and with more slowly developing neurologic and locomotor impairment. The patient was found to be compound heterozygous with a missense mutation resulting in an R5G amino acid substitution and a frameshift mutation that is a predicted null allele. To better understand disease pathogenesis in this patient, we expressed and purified the TPIR5G human protein and studied it biochemically in addition to studying TPIR5G/f.s.patient cells. We discovered that purified TPIR5G protein has wildtype activity with modestly increased dimer stability. We also discovered that steady-state TPI protein levels were markedly reduced, suggesting that the instability of the mutant protein underlies disease pathogenesis. We tested compounds recently identified in a screen for novel TPI Df therapies for their efficacy in TPIR5G/f.s.patient cells. All three compounds significantly increased TPI protein levels in patient cells. As expected, since the mutant protein retains essentially wild type activity, the increase in TPI protein levels also resulted in a significant increase in TPI activity. Conclusions: These results establish TPIR5G as a TPI Df allele, demonstrate that reduced stability of the mutant protein underlies pathogenesis akin to other disease-causing alleles, and suggest that recently discovered developing therapies will likely function broadly and should be developed as potential TPI Df therapies.Keywords
Funding Information
- National Institutes of Health (R01 HD105311, R01 HD104346, S10 OD028450)
- TPI Deficiency Research Fund
This publication has 18 references indexed in Scilit:
- Discovery and validation of small molecule stabilizers of mutant triose phosphate isomerase (TPI) as potential lead candidates for TPI deficiencySLAS Discovery, 2025
- TPI deficiency: A case report and review of the literatureMolecular Genetics and Metabolism, 2025
- Neuromuscular dysfunction and pathogenesis in triosephosphate isomerase deficiencyScientific Reports, 2024
- Identification of protein quality control regulators using a Drosophila model of TPI deficiencyNeurobiology of Disease, 2021
- Missense variant in TPI1 (Arg189Gln) causes neurologic deficits through structural changes in the triosephosphate isomerase catalytic site and reduced enzyme levels in vivoBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Differential effects on enzyme stability and kinetic parameters of mutants related to human triosephosphate isomerase deficiencyBiochimica et Biophysica Acta (BBA) - General Subjects, 2018
- Hsp70- and Hsp90-mediated proteasomal degradation underlies TPIsugarkill pathogenesis in DrosophilaNeurobiology of Disease, 2010
- Triosephosphate isomerase deficiency: New insights into an enigmatic diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Triosephosphate isomerase deficiency: historical perspectives and molecular aspectsBest Practice & Research Clinical Haematology, 2000
- Perfection in enzyme catalysis: the energetics of triosephosphate isomeraseAccounts of Chemical Research, 1977